Burlington, MA, United States
Burlington, MA, United States

Time filter

Source Type

News Article | February 17, 2017
Site: www.PR.com

Receive press releases from Laboratory Testing Inc.: By Email A degreed industrial engineer was promoted to Project Manager at Laboratory Testing Inc. In his new position, Dan Giordano will coordinate the implementation of a company-wide ERP System. Philadelphia, PA, February 17, 2017 --( Dan is a May 2014 graduate of Penn State University with a B.S. degree in Industrial Engineering. His career at Lab Testing began upon graduation, when he joined the company as an Industrial Engineering Intern in the Mechanical Testing Department and Machine Shop. He was hired as a full-time employee two months later and given the title Machine Shop Workflow Coordinator. During the first year, he started to transition into his next role as Project Engineer by expanding the types and size of projects he coordinated for both Mechanical Testing and the Machine Shop. “Both departments have gone through extensive development and change during Dan’s time, and he has been a key member of the implementation teams,” said Mike McVaugh. The Mechanical Testing Department provides a wide-range of services that evaluate the mechanical properties of metals and polymers, from tensile and hardness testing to charpy impact, stress rupture and fracture mechanics. The in-house Machine Shop produces all test specimens required to fill mechanical testing orders at LTI and also prepares specimens for customers who perform their own testing. The ERP system will be implemented in all three production departments, Destructive Testing, Non-Destructive Testing and Metrology, as well as most support departments, including Sales, Machine Shop, Order Entry, Shipping/Receiving and Accounting. The System will allow LTI to work more efficiently and improve collaboration between departments. About Laboratory Testing Inc. - Laboratory Testing Inc. (LTI) of Hatfield, PA is an independent materials testing and metrology laboratory in business since 1984. The range of services offered by LTI includes mechanical testing, metallurgical testing, chemical analysis, corrosion testing, nondestructive testing, specimen machining, failure analysis, dimensional inspection and calibration services with results documented in a Certified Test Report or Calibration Certificate. The laboratory specializes in metal and polymer testing, but also analyzes powdered metals, ores, ferroalloys, composites and ceramics. LTI holds PRI/Nadcap accreditations in materials and nondestructive testing, and A2LA accreditations to ANS/ISO/IEC 17025 in materials testing, dimensional inspection and calibration services, which complies with ISO 9001 and ISO 13485. Test specimens are machined on-site and material investigations are conducted to determine the root cause of material failures. LTI Metrology, a division of Laboratory Testing Inc., provides dimensional inspection and NIST-traceable calibration services for measuring hand tools, masters and a wide-range of measuring instruments and equipment. On-site calibration, repairs, new instruments and replacement parts are offered. Information on Laboratory Testing Inc. services and accreditations is available at www.labtesting.com, sales@labtesting.com or 800-784-2882. Philadelphia, PA, February 17, 2017 --( PR.com )-- Dan Giordano has been promoted to Project Manager at Laboratory Testing Inc. to oversee the implementation of an enterprise resource planning (ERP) System. Dan will be responsible for the day-to-day management of this project and the various project teams. According to Mike McVaugh, CEO and President of LTI, “Not only will he oversee the activities of the core and extended project teams at LTI, but he will also act as the principal liaison between LTI’s project teams and our external partner, Decision Resources Inc.”Dan is a May 2014 graduate of Penn State University with a B.S. degree in Industrial Engineering. His career at Lab Testing began upon graduation, when he joined the company as an Industrial Engineering Intern in the Mechanical Testing Department and Machine Shop. He was hired as a full-time employee two months later and given the title Machine Shop Workflow Coordinator. During the first year, he started to transition into his next role as Project Engineer by expanding the types and size of projects he coordinated for both Mechanical Testing and the Machine Shop. “Both departments have gone through extensive development and change during Dan’s time, and he has been a key member of the implementation teams,” said Mike McVaugh.The Mechanical Testing Department provides a wide-range of services that evaluate the mechanical properties of metals and polymers, from tensile and hardness testing to charpy impact, stress rupture and fracture mechanics. The in-house Machine Shop produces all test specimens required to fill mechanical testing orders at LTI and also prepares specimens for customers who perform their own testing.The ERP system will be implemented in all three production departments, Destructive Testing, Non-Destructive Testing and Metrology, as well as most support departments, including Sales, Machine Shop, Order Entry, Shipping/Receiving and Accounting. The System will allow LTI to work more efficiently and improve collaboration between departments.About Laboratory Testing Inc. - Laboratory Testing Inc. (LTI) of Hatfield, PA is an independent materials testing and metrology laboratory in business since 1984. The range of services offered by LTI includes mechanical testing, metallurgical testing, chemical analysis, corrosion testing, nondestructive testing, specimen machining, failure analysis, dimensional inspection and calibration services with results documented in a Certified Test Report or Calibration Certificate. The laboratory specializes in metal and polymer testing, but also analyzes powdered metals, ores, ferroalloys, composites and ceramics. LTI holds PRI/Nadcap accreditations in materials and nondestructive testing, and A2LA accreditations to ANS/ISO/IEC 17025 in materials testing, dimensional inspection and calibration services, which complies with ISO 9001 and ISO 13485. Test specimens are machined on-site and material investigations are conducted to determine the root cause of material failures. LTI Metrology, a division of Laboratory Testing Inc., provides dimensional inspection and NIST-traceable calibration services for measuring hand tools, masters and a wide-range of measuring instruments and equipment. On-site calibration, repairs, new instruments and replacement parts are offered. Information on Laboratory Testing Inc. services and accreditations is available at www.labtesting.com, sales@labtesting.com or 800-784-2882. Click here to view the list of recent Press Releases from Laboratory Testing Inc.


You J.J.,McMaster University | Singer D.E.,Massachusetts General Hospital | Howard P.A.,University of Kansas Medical Center | Lane D.A.,University of Birmingham | And 10 more authors.
Chest | Year: 2012

Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is associated with an increased risk of bleeding. We provide recommendations for antithrombotic treatment based on net clinical benefi t for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios. Methods: We used the methods described in the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines article of this supplement. Results: For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS 2 [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS 2 score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS 2 score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel. Where we recommend or suggest in favor of oral anticoagulation, we suggest dabigatran 150 mg bid rather than adjusted-dose vitamin K antagonist therapy. Conclusions: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF at high risk of stroke (CHADS 2 score of ≥ 2). At lower levels of stroke risk, antithrombotic treatment decisions will require a more individualized approach. © 2012 American College of Chest Physicians.


Bickham D.S.,Boston Childrens Hospital | Bickham D.S.,Harvard University | Blood E.A.,Boston Childrens Hospital | Blood E.A.,Harvard University | And 6 more authors.
Pediatrics | Year: 2013

OBJECTIVES: This study investigates how characteristics of young adolescents' screen media use are associated with their BMI. By examining relationships between BMI and both time spent using each of 3 screen media and level of attention allocated to use, we sought to contribute to the understanding of mechanisms linking media use and obesity. METHODS: We measured heights and weights of 91 13- to 15-year-olds and calculated their BMIs. Over 1 week, participants completed a weekday and a Saturday 24-hour time-use diary in which they reported the amount of time they spent using TV, computers, and video games. Participants carried handheld computers and responded to 4 to 7 random signals per day by completing onscreen questionnaires reporting activities to which they were paying primary, secondary, and tertiary attention. RESULTS: Higher proportions of primary attention to TV were positively associated with higher BMI. The difference between 25th and 75th percentiles of attention to TV corresponded to an estimated +2.4 BMI points. Time spent watching television was unrelated to BMI. Neither duration of use nor extent of attention paid to video games or computers was associated with BMI. CONCLUSIONS: These findings support the notion that attention to TV is a key element of the increased obesity risk associated with TV viewing. Mechanisms may include the influence of TV commercials on preferences for energy-dense, nutritionally questionable foods and/or eating while distracted by TV. Interventions that interrupt these processes may be effective in decreasing obesity among screen media users. Copyright © 2013 by the American Academy of Pediatrics.


Richmond T.K.,Boston Childrens Hospital | Thurston I.,University of Memphis | Sonneville K.,Boston Childrens Hospital | Milliren C.E.,Boston Childrens Hospital | And 3 more authors.
International Journal of Obesity | Year: 2015

Surveillance data describing the weight status of the US population often rely on self-reported height and weight, despite likely differences in reporting accuracy by demographics. Our objective was to determine if there were racial/ethnic differences in accuracy of self-reported body mass index (BMI) in a diverse nationally representative sample of young people. Using data from Wave III (data collected in 2001-2002) of the National Longitudinal Study of Adolescent Health when respondents were aged 18-26, we used gender-stratified multivariable linear regression models to examine the association of race/ethnicity and self-reported BMI controlling for measured BMI while also adjusting for factors known to be associated with weight self-perception. Black males and females (b Female =0.45, confidence interval (CI): 0.19, 0.71; b Male =0.34, CI: 0.17, 0.51) and Hispanic females (b Female =0.30, CI: 0.08, 0.52) and Native American males (b Native American =0.87, CI: 0.15, 1.58) reported higher BMIs than their similarly weighted White peers, leading to more accurate BMI reporting in these groups at higher BMIs. Caution should be taken in interpreting results from studies relying on self-reported BMI, as they may exaggerate racial/ethnic differences in weight status. © 2015 Macmillan Publishers Limited.


PubMed | Boston Childrens Hospital and Decision Resources Inc.
Type: Journal Article | Journal: Journal of pediatric and adolescent gynecology | Year: 2015

To review the clinical presentation, evaluation, and management of normal-weight (NW), overweight (OW), and obese (OB) adolescent and young adult women with polycystic ovary syndrome (PCOS) during a 2-year follow-up.Retrospective chart review.One hundred seventy-three adolescent and young adult women, aged 12-22 years, diagnosed with PCOS.Demographic, health data, and laboratory measures were abstracted from 3 clinic visits: baseline and 1- and 2-year follow-up. Subjects were classified as NW, OW, or OB. Longitudinal data were analyzed using repeated-measures analysis of variance.Body mass index, self-reported concerns, and lifestyle changes.Most patients (73%) were OW or OB. Family history of type 2 diabetes was greater in OW (38%) and OB (53%) patients compared with NW (22%) patients (P = .002). Acanthosis nigricans was identified in OW (62%) and OB (21%) patients but not in NW patients (0%; P < .001). OW and OB patients had higher fasting insulin (P < .001) and lower high-density lipoprotein cholesterol (P = .005) levels than NW patients, although screening rates were low. Body mass index Z-scores decreased in both OW and OB patients over time (0.07 unit/yr, P < .001).Most patients with PCOS were OW or OB. Substantial clinical variability existed in cardiovascular disease (CVD) screening; among those screened, OW and OB patients had greater CVD risk factors. Despite self-reported concerns about weight and diabetes risk among OW and OB patients, no clinically significant change in body mass index percentile occurred. Evidence-based interventions and recommendations for screening tests are needed to address CVD risk in adolescents and young adults with PCOS.


Blagovic K.,Massachusetts Institute of Technology | Kim L.Y.,Massachusetts Institute of Technology | Kim L.Y.,Decision Resources Inc. | Voldman J.,Massachusetts Institute of Technology
PLoS ONE | Year: 2011

Background: Autocrine & paracrine signaling are widespread both in vivo and in vitro, and are particularly important in embryonic stem cell (ESC) pluripotency and lineage commitment. Although autocrine signaling via fibroblast growth factor-4 (FGF4) is known to be required in mouse ESC (mESC) neuroectodermal specification, the question of whether FGF4 autocrine signaling is sufficient, or whether other soluble ligands are also involved in fate specification, is unknown. The spatially confined and closed-loop nature of diffusible signaling makes its experimental control challenging; current experimental approaches typically require prior knowledge of the factor/receptor in order to modulate the loop. A new approach explored in this work is to leverage transport phenomena at cellular resolution to downregulate overall diffusible signaling through the physical removal of cell-secreted ligands. Methodology/Principal Findings: We develop a multiplex microfluidic platform to continuously remove cell-secreted (autocrine\paracrine) factors to downregulate diffusible signaling. By comparing cell growth and differentiation in side-by-side chambers with or without added cell-secreted factors, we isolate the effects of diffusible signaling from artifacts such as shear, nutrient depletion, and microsystem effects, and find that cell-secreted growth factor(s) are required during neuroectodermal specification. Then we induce FGF4 signaling in minimal chemically defined medium (N2B27) and inhibit FGF signaling in fully supplemented differentiation medium with cell-secreted factors to determine that the non-FGF cell-secreted factors are required to promote growth of differentiating mESCs. Conclusions/Significance: Our results demonstrate for the first time that flow can downregulate autocrine\paracrine signaling and examine sufficiency of extracellular factors. We show that autocrine\paracrine signaling drives neuroectodermal commitment of mESCs through both FGF4-dependent and -independent pathways. Overall, by uncovering autocrine\paracrine processes previously hidden in conventional culture systems, our results establish microfluidic perfusion as a technique to study and manipulate diffusible signaling in cell systems. © 2011 Blagovic et al.


Trademark
Decision Resources Inc. | Date: 2015-09-04

Downloadable electronic publications in the nature of reports, white papers, newsletters, articles, and brochures, in the fields of pharmaceuticals, biopharmaceuticals, and the life sciences; downloadable webinars, webcasts, and podcasts in the fields of pharmaceuticals, biopharmaceuticals, and the life sciences.


Trademark
Decision Resources Inc. | Date: 2013-05-07

Computer databases for pharmaceutical research, development, marketing and planning in the pharmaceutical industry; downloadable electronic publications in the nature of periodic reports in the field of medical devices and medical disorders, namely, medical information on products, markets, industry, technologies, treatment, companies, procedures and therapies; downloadable electronic reports and databases on the subjects of medical, diagnostic and imaging equipment, and other medical products used in hospitals; downloadable electronic reports and databases on the subjects of the markets for, and usage of, such pharmaceuticals, equipment and products used in hospitals; downloadable webinars in the field of medical information on products, markets, industry, technologies, treatment, companies, procedures and therapies. Consulting services related to pharmaceutical market research; providing product and service information to the pharmaceutical and medical device marketing and manufacturing industries in the field of medical disorders, namely, information on products that are available for use in connection with various medical technologies, medical treatments and medical therapies, information on the companies and industries that are providing and developing such products, technologies, treatments and therapies, and information on the current and potential markets for such products, technologies, treatments and therapies; providing an electronic database featuring business information about integrated managed care enrollment, market share and plan data; providing an electronic database featuring business information about integrated managed care enrollment, market share and plan data; syndicated market research for health and pharmaceutical companies; marketing consulting and primary market research services with respect to market access, managed markets, pricing, and reimbursement; consulting in the field of database management, specifically for databases for pharmaceutical research, marketing, development; analysis of market research data in the field of prescription drugs; providing an online database in the field of business information for use in research, development, marketing and planning in the pharmaceutical industry. Seminars on business management and marketing strategies for healthcare and pharmaceutical companies; Providing online non-downloadable electronic reports regarding forecasts and analysis of current emerging technologies, their applications and markets; Providing online non-downloadable electronic reports regarding various products for markets, industries and technologies related to medical disorders; providing online non-downloadable electronic reports in the field of research, development, marketing and planning in the pharmaceutical industry. Providing online non downloadable software which allows users to access computer databases for biopharmaceutical research and development; providing a website featuring online non-downloadable software which allows users to access electronic reports and databases stored electronically in central files for remote consultation containing information on health systems, hospitals, physicians, health plans, Medicare and Medicaid, health-related legislation. Providing information in the field of medical disorders, namely, medical information on medical products, medical technologies, medical treatments and medical therapies.


Trademark
Decision Resources Inc. | Date: 2013-05-07

Computer databases for pharmaceutical research, development, marketing and planning in the pharmaceutical industry; downloadable electronic publications in the nature of periodic reports in the field of medical devices and medical disorders, namely, medical information on products, markets, industry, technologies, treatment, companies, procedures and therapies; downloadable electronic reports and databases on the subjects of medical, diagnostic and imaging equipment, and other medical products used in hospitals; downloadable electronic reports and databases on the subjects of the markets for, and usage of, such pharmaceuticals, equipment and products used in hospitals; downloadable webinars in the field of medical information on products, markets, industry, technologies, treatment, companies, procedures and therapies. Consulting services related to pharmaceutical market research; providing product and service information to the pharmaceutical and medical device marketing and manufacturing industries in the field of medical disorders, namely, information on products that are available for use in connection with various medical technologies, medical treatments and medical therapies, information on the companies and industries that are providing and developing such products, technologies, treatments and therapies, and information on the current and potential markets for such products, technologies, treatments and therapies; providing an electronic database featuring business information about integrated managed care enrollment, market share and plan data; providing an electronic database featuring business information about integrated managed care enrollment, market share and plan data; syndicated market research for health and pharmaceutical companies; marketing consulting and primary market research services with respect to market access, managed markets, pricing, and reimbursement; consulting in the field of database management, specifically for databases for pharmaceutical research, marketing, development; analysis of market research data in the field of prescription drugs; providing an online database in the field of business information for use in research, development, marketing and planning in the pharmaceutical industry. Seminars on business management and marketing strategies for healthcare and pharmaceutical companies; Providing online non-downloadable electronic reports regarding forecasts and analysis of current emerging technologies, their applications and markets; Providing online non-downloadable electronic reports regarding various products for markets, industries and technologies related to medical disorders; providing online non-downloadable electronic reports in the field of research, development, marketing and planning in the pharmaceutical industry. Providing online non downloadable software which allows users to access computer databases for biopharmaceutical research and development; providing a website featuring online non-downloadable software which allows users to access electronic reports and databases stored electronically in central files for remote consultation containing information on health systems, hospitals, physicians, health plans, Medicare and Medicaid, health-related legislation. Providing information in the field of medical disorders, namely, medical information on medical products, medical technologies, medical treatments and medical therapies.


Trademark
Decision Resources Inc. | Date: 2010-03-23

Downloadable Electronic Reports on the subjects of the formulary status of drugs and pharmaceutical products for various diseases.

Loading Decision Resources Inc. collaborators
Loading Decision Resources Inc. collaborators